INTRA-CELLULAR THERAPIES INC. - COMMON STOCK

Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

04 May 2023 06:30:56 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

02 May 2023 07:00:39 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

26 Apr 2023 07:00:43 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 07:00:35 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features

28 Mar 2023 06:00:12 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

01 Mar 2023 06:30:35 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast

14 Feb 2023 07:00:33 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference

08 Feb 2023 07:00:59 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:24 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting

08 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences

10 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

03 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast

27 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast

02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience

13 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

10 May 2022 06:30:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

25 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

21 Apr 2022 07:00:02 By Nasdaq GlobeNewswire